Clinical Trial Update: LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy [Phase 3]

View source ↗

Summary

Phase III trial evaluating Afatinib versus placebo for head and neck squamous cell carcinoma after chemoradiotherapy; the study was terminated and results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Head and Neck Neoplasms | Phase 3 | Status: TERMINATED | Results posted: 2017-10-23